LUOTAI group treated with LUOTAI with dosage, dosing schedule and duration follows local clinical practice in accordance with the terms of the local marketing authorization: 400mg of LUOTAI injectable lyophilized powder diluted in 250ml of 5% Glucose Solution or 0.9% Normal Saline for included diabetic patients, via slow intravenous infusion, once daily for consecutive 14 days, and followed by 200mg of LUOTAI soft capsules, three times a day for 65 days.

Control group comprises of patients who are not treated with LUOTAI, and follows local clinical practice for ischemic stroke.

Infarction, Anterior Cerebral Artery

Infarction, Middle Cerebral Artery

Ischemic Attack, Transient

Bach Mai Hospital

Phu Tho General Hospital

103 Military Hospital

An Observational Registry Study of LUOTAI in Patients With Acute Ischemic Stroke in Vietnam

A Non-interventional, Controlled, Open-label, Observational Registry Study to Investigate the Safety and Effectiveness of LUOTAI (Panax Notoginseng) Injectable and Soft Capsules in Patients With Acute Ischemic Stroke in Vietnam

Modified Rankin Scale (mRS) is an overall functional outcome measure, measuring stroke defect. Answer the test questions for 5-10 minutes. The score range is 7 points with a score of 0 for the absence of sequelae and the worst possible score is 6.
0 - No symptoms.
- No significant disability. Able to carry out all usual activities, despite some symptoms.
- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
- Moderate disability. Requires some help, but able to walk unassisted.
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
- Dead. Primary Efficacy Endpoint defined as "Categorical shift in mRS score at 3 months (ordinal logistic regression analysis of the mRS on Day 90)".

Ordinal NIHSS at 3 months after stroke onset

Ordinal MoCA at 3 months after stroke onset

Proportion of patients with excellent recovery and functional dependence at 3 months after stroke onset (mRC=0 or 1)

KPC Pharmaceuticals, Inc

both a ginsenoside-Rd injection (10mg/1ml/each) and a specific dilution (10%, 1ml trimethylene glycol) were respectively diluted by a specific dilution (10%, 9 ml trimethylene glycol) and then mixed.

2 specific dilutions (10%, 1ml trimethylene glycol) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed.

2 ginsenoside-Rd injections (10mg/1ml/each) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed

Ischemic Stroke

infusion ginsenoside-Rd 10 mg (group A)once a day and continued for 14 days

ginsenoside-Rd 10 mg

infusion placebo (group B)once a day and continued for 14 days

placebo

infusion of ginsenoside-Rd 20mg (group C) once a day and continued for 14 days

ginsenoside m 5/infarction

An Observational Registry Study of LUOTAI in Patients With Acute Ischemic Stroke in Vietnam

Ginsenoside-Rd for Acute Ischemic Stroke

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht